You are viewing: China Genotyping Assay Market analysis
Part of: Genotyping Assay Market (Global)

The China Genotyping Assay Market was valued at $724.5 Million in 2024 and projected to reach to $1647.7 Million by 2029, representing a compound annual growth rate of CAGR 17.9%. China's genotyping assay market is poised for exceptional growth through 2029, driven by government-backed precision medicine initiatives and substantial investments in genomic research infrastructure.

China Genotyping Assay Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Genotyping Assay Market Trends and Insights

  • This represents a compound annual growth rate of 17.9%, significantly outpacing global market growth.
  • China's rapid advancement in genomic research, coupled with increasing government investment in precision medicine initiatives, is driving substantial demand for genotyping assays across clinical diagnostics, pharmaceutical development, and agricultural applications. The market growth in China is fueled by rising healthcare expenditure, expanding laboratory infrastructure, and growing adoption of personalized medicine practices.
  • China's large population base and increasing prevalence of genetic disorders create substantial opportunities for genotyping assay providers.
  • Between 2024 and 2029, China is expected to consolidate its position as a key regional hub for genomic testing, supported by technological innovation and regulatory framework improvements that facilitate market entry and clinical adoption..

Key Market Statistics

  • CAGR (2024-2029) CAGR 17.9%
  • Market Size, 2024 ~USD 724.5 Million
  • Forecast, 2029 ~USD 1647.7 Million
  • Country China

China Genotyping Assay Market Overview

Exceptional Growth Trajectory :

China's genotyping assay market is expanding at 17.9% CAGR, nearly 30% faster than the global average of 13.8%, reflecting strong domestic demand and accelerating adoption across healthcare institutions.

Government-Backed Precision Medicine :

Substantial government investment in precision medicine initiatives and genomic research infrastructure is catalyzing market expansion, positioning China as a leading hub for genotyping technology development and deployment.

Rapid Market Valuation Growth :

The market is projected to more than double from USD 724.5 million in 2024 to USD 1,647.7 million by 2029, demonstrating China's commitment to advancing personalized healthcare and genetic diagnostics.

Genomic Research Advancement :

China's rapid advancement in genomic research capabilities, combined with increasing healthcare spending and population awareness, is driving substantial demand for genotyping assays across clinical and research settings.

China Genotyping Assay Market Dynamics

  • The country's healthcare modernization agenda prioritizes personalized medicine, creating robust demand for advanced genotyping technologies across hospitals, diagnostic centers, and research institutions. The market's 17.9% CAGR significantly outpaces global growth, reflecting China's strategic focus on genetic diagnostics and precision healthcare.
  • Increasing healthcare expenditure, rising disease prevalence, and growing adoption of genomic testing in clinical practice will continue to fuel expansion, positioning China as a critical growth engine in the global genotyping assay market..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Danaher Corporation

    Key Takeaways

    • China's genotyping assay market is valued at USD 724.5 million in 2024 and is forecast to grow to USD 1,647.7 million by 2029, representing a 17.9% CAGR.
    • China's market growth significantly exceeds the global CAGR of 13.8%, driven by government precision medicine initiatives and expanding healthcare infrastructure.
    • China's large population and rising genetic disorder prevalence create substantial demand for genotyping assays across clinical, pharmaceutical, and agricultural sectors.
    • China's regulatory improvements and technological innovation are positioning the country as a key regional hub for genomic testing and personalized medicine adoption.

    Genotyping Assay Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment PHARMACOGENOMICS (Application)
    Forecast Period 2024–2029
    Growth Rate CAGR of 13.8% from 2024 to 2029
    Largest Segment REAGENTS & KITS (Product & Service)
    Market Size Base Year (Billions) ~USD 19.44 (2024)
    Revenue Forecast (Billions) ~USD 37.1 (2029)
    Segments Covered Product & Service, Type, Technology, Application, End User

    China Genotyping Assay Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product & Service

    • Bioinformatics
    • Genotyping Services
    • Instruments
    • Reagents & Kits

    By Type

    • Amplified Fragment Length Polymorphism
    • Analyzers
    • Digital Polymerase Chain Reaction
    • Next-Generation Sequencing
    • Pyrosequencing
    • Real-Time Polymerase Chain Reaction
    • Restriction Fragment Length Polymorphism
    • Sanger Sequencing
    • Sequencers & Amplifiers
    • Services
    • Single-Strand Confirmation Polymorphism
    • Software

    By Technology

    • Capillary Electrophoresis
    • Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry
    • Microarrays
    • Other Technologies
    • Polymerase Chain Reaction
    • Sequencing

    By Application

    • Agricultural Biotechnology
    • Animal Genetics
    • Diagnostics & Personalized Medicines
    • Other Applications
    • Pharmacogenomics

    By End User

    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES223.1322368.2423.7490.7571.7670.2790.616.5
    DIAGNOSTIC LABORATORIES267.2305.6352408475.9558.5659.5783.417.3
    OTHER END USERS262.2227.7258.6295.7340.1393.7458.5537.215.7
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES320.7371.2432.5506.8597.5708.5845.1101418.6
    TOTAL1073.21226.51411.31634.31904.22232.42633.33125.117.2

    Target Audience

    • In Vitro Diagnostics (IVD) Manufacturers : Need China-specific market data to assess market opportunity, plan product localization, and develop competitive strategies for genotyping assay portfolios in the world's fastest-growing genomic diagnostics market.
    • Healthcare Investment & Private Equity Firms : Require validated market sizing and growth projections for China to evaluate investment opportunities in genomic diagnostics companies, precision medicine platforms, and healthcare technology ventures.
    • Pharmaceutical & Biotech Companies : Need China market intelligence to support companion diagnostic development, precision medicine drug strategies, and partnerships with local diagnostic providers in this high-growth genomic testing market.
    • Hospital & Diagnostic Laboratory Networks : Seek market outlook data to justify capital investments in genotyping infrastructure, plan service expansion, and benchmark competitive positioning within China's rapidly evolving precision medicine ecosystem.
    • Government & Healthcare Policy Makers : Require comprehensive market analysis to inform precision medicine policy development, healthcare infrastructure planning, and resource allocation for genomic research initiatives across Chinese healthcare systems.

    Key Companies in the China Genotyping Assay Market

    CompanyHQOwnershipStrongest segments
    SEQUENOM,INC.United StatesPrivate CompanyMaterniT21 PLUS and VisibiliT NIPT,MaterniT21 GENOME and microarray (NextView),HerediT carrier screening (CF, Ashkenazi, SMA, fragile X),
    DECODE GENETICSIcelandPrivate CompanyTarget discovery and validation for Amgen pipeline,Large-scale genome sequencing and analytics services,Data access, licensing, and collaborative research programs,
    TRANSGENOMIC, INC.United StatesPublic CompanyOncology and pharmacogenomics clinical trial services,Clinical oncology testing services (patient diagnostics and monitoring),Multiplexed ICE COLD-PCR reagents and technology licensing,
    IMMUCOR, INC.United StatesPrivate CompanyTransfusion serology reagents (manual and Capture),Automated serology instruments (NEO, Echo, Capture Workstation),Transplant & molecular assays (HEA/HPA typing, Array Imaging System, BASIS),
    GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines OE,Commercial Engines Services & MRO,Defense & Propulsion Technologies – Engines,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    ILLUMINA, INC.United StatesPublic CompanySequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Array-based instruments and consumables,
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology,Life Sciences,Diagnostics,
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health),PCR and enzymes (qPCR, dPCR, research PCR kits),
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Tools,Other / Services and Software,
    MERCK KGAAGermanyPublic CompanyLife Science (lab reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, immunology, fertility, rare diseases),Electronics (semiconductor materials, specialty gases, display and OLED materials),
    STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics and qPCR systems (Biomark X9 and related assays),Services, software, and other consumables,
    REVVITYUnited StatesPublic CompanyDiagnostics instruments and automation (AutoDELFIA, GSP, EUROIMMUN, IDS-iSYS, EUROLabWorkstation),Diagnostics reagents, assays, and kits (prenatal, newborn, autoimmune, infectious disease, T-SPOT),Life science reagents and consumables (BioLegend, Dharmacon, NEXTFLEX, AlphaLISA portfolio),
    PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read instruments and consumables (Onso platform),
    OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION platforms and consumables,MinION and portable platforms,GridION and mid-throughput systems,

    SEQUENOM,INC.

    Sequenom, Inc. is a private molecular diagnostics company founded in 1994 in the United States with 434 employees. The company specializes in genetic testing and analysis.

    DECODE GENETICS

    Decode Genetics is a private genomics and biotechnology company founded in 1996 in Iceland with 331 employees. The company conducts genetic research and develops diagnostics based on genomic data.

    TRANSGENOMIC, INC.

    Transgenomic, Inc. is a public molecular diagnostics company founded in 1997 in the United States with 19 employees. The company develops genetic testing and analysis technologies.

    IMMUCOR, INC.

    Immucor, Inc. is a private blood bank and transfusion diagnostics company founded in 1982 in the United States with 1,125 employees. The company provides immunohematology and transfusion medicine solutions.

    GENERAL ELECTRIC

    General Electric is a public multinational conglomerate founded in 1892 in the United States with 57,000 employees. The company operates across diverse industries including healthcare, energy, and industrial sectors.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public life sciences and diagnostics company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.

    ILLUMINA, INC.

    Illumina, Inc. is a public genomics and sequencing company founded in 1998 in the United States with 8,625 employees. The company develops DNA sequencing and genetic analysis technologies.

    DANAHER CORPORATION

    Danaher Corporation is a public diversified conglomerate founded in 1969 in the United States with 59,000 employees. The company operates across life sciences, diagnostics, and environmental solutions.

    QIAGEN

    Qiagen is a public molecular diagnostics and life sciences company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample preparation, assay, and sequencing technologies.

    EUROFINS SCIENTIFIC

    Eurofins Scientific is a public laboratory services and diagnostics company founded in 1987 in Luxembourg with 65,694 employees. The company operates a global network of laboratories providing testing and analysis services.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. is a public life sciences and diagnostics company founded in 1999 in the United States with 18,000 employees. The company manufactures analytical instruments and laboratory equipment.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public life sciences and diagnostics company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures clinical diagnostics and life science research products.

    MERCK KGAA

    Merck KGaA is a public pharmaceutical and life sciences company founded in 1668 in Germany with 59,077 employees. The company provides pharmaceuticals, chemicals, and laboratory solutions globally.

    STANDARD BIOTOOLS

    Standard Biotools is a public life sciences instrumentation company founded in 1999 in the United States with 387 employees. The company develops microfluidics and single-cell analysis technologies.

    REVVITY

    Revvity is a public life sciences and diagnostics company founded in 1937 in the United States with 11,000 employees. The company provides analytical instruments, reagents, and software solutions.

    PACBIO

    PacBio is a public genomics sequencing company founded in 2000 in the United States with 485 employees. The company develops long-read DNA sequencing technologies.

    OXFORD NANOPORE TECHNOLOGIES PLC

    Oxford Nanopore Technologies PLC is a public genomics sequencing company founded in 2005 in the United Kingdom with 1,316 employees. The company develops portable DNA and RNA sequencing technologies.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for China (USD 724.5M in 2024) with verified 17.9% CAGR projections through 2029, enabling accurate financial forecasting and investment decision-making for regional expansion strategies.
    • Competitive Positioning Intelligence : Understand China's market dynamics relative to global trends (13.8% CAGR), identifying competitive advantages and market gaps specific to Chinese healthcare infrastructure and regulatory environment.
    • Government Initiative Insights : Access detailed analysis of China's precision medicine investments and genomic research funding, helping stakeholders align product development and market entry strategies with government priorities and policy drivers.
    • Demand Forecasting & Planning : Leverage comprehensive 5-year forecast data to project market demand, capacity requirements, and revenue potential across Chinese healthcare institutions, diagnostic centers, and research organizations.
    • Strategic Market Entry Framework : Develop informed go-to-market strategies for China with localized insights on adoption rates, healthcare spending patterns, and institutional preferences specific to the genotyping assay sector.

    Frequently asked questions

    What is the current size of China's genotyping assay market?

    China's genotyping assay market was valued at USD 724.5 million in 2024 and is expected to grow to USD 1,647.7 million by 2029.

    What is the projected growth rate for China's genotyping assay market?

    China's genotyping assay market is projected to grow at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2029.

    How does China's market growth compare to global trends?

    China's genotyping assay market CAGR of 17.9% significantly outpaces the global CAGR of 13.8%, reflecting stronger regional demand and investment.

    What are the primary drivers of growth in China's genotyping assay market?

    Key drivers include government precision medicine initiatives, rising healthcare expenditure, expanding laboratory infrastructure, and increasing adoption of personalized medicine practices in China.

    Which sectors are driving demand for genotyping assays in China?

    Demand in China is driven by clinical diagnostics, pharmaceutical development, agricultural applications, and personalized medicine initiatives across healthcare institutions.

    RESEARCH METHODOLOGY

    The objective of the study is analyzing the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the genotyping assay market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Breakdown Of Primary Participants:

    Genotyping  Assay Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME

    DESIGNATION

    F. Hoffmann-La Roche Ltd. (Switzerland)

    Marketing Manager

    Thermo Fisher Scientific, Inc. (US)

    Senior Product Manager

    QIAGEN N.V. (Netherlands)

    Marketing Manager

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the home healthcare market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the genotyping assay market have been determined through primary and secondary research
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Global genotyping assay Market Size: Bottom-Up Approach

    Genotyping  Assay Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Global genotyping assay Market Size: Top-Down Approach

    Genotyping  Assay Market Size, and Share

    Data Triangulation

    After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Genotyping is used to study the differences in the genetic makeup (specific genome variants) of cells, microorganisms, plants, animals, and individuals. These differences in genotypes are determined by studying individual DNA sequences using biological assays and comparing them with other reference sequences. This process has wide applications in the field of life sciences, including animal genetics, diagnostic research, & pharmacogenomics, agricultural biotechnology, and personalized medicine.

    Key Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global genotyping assay market by product and services, technology, application, enduser, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall genotyping assay market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries.
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report

    Country Information

    • Additional country-level analysis of the genotyping assay market

    Company profiles

    • Additional five company profiles of players operating in the genotyping assay market.

    Product Analysis

    • Product matrix, which provides a detailed comparison of the product portfolio of each company in the genotyping assay market

    Get the Full Genotyping Assay Market Report

    Full forecast, segment splits, and company analysis for all Genotyping Assay Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status